Newronika's AlphaDBS Receives European CE Mark for Adaptive Deep Brain Stimulation in Parkinson's Disease
Shots:
- Newronika has reported European CE Mark approval for its AlphaDBS device for Parkinson's Disease following the grant of the US FDA’s IDE approval; commercially available in select EU countries in 2025
- Approval was based on clinical evidence showing longer symptom-free periods compared to traditional DBS, with benefits observed across safety, quality of life, & higher pts preference for adaptive stimulation
- AlphaDBS monitors brain activity & auto-adjusts stimulation based on real-time neurophysiological feedback, allowing enhanced symptom control, reduced side effects, & limited need for adjustments by neurologists
Ref: Prnewswire | Image: Newronika
Related News:- Moon Surgical Reports US FDA’s 510(k) Clearance of ScoPilot to Improve Intraoperative Capability
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
